Details of the Drug Reposition

General Information of This Drug (ID: DM9L1AC)

Drug Name
SYR-472   DM9L1AC
Synonyms
Trelagliptin succinate; TRELAGLIPTIN SUCCINATE; 1029877-94-8; Trelagliptin (succinate); UNII-4118932Z90; AK198895; 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile; 4118932Z90; SYR-472 succinate; (R)-2-((6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)-4-fluorobenzonitrile succinate; SYR 111472 succinate; Trelagliptin succinate [USAN]; SYR111472 SUCCINATE; SYR 472; SYR472; Zafatek (TN); Trelagliptin succinat; SYR472 succinate; syr; Trelagliptin Succinate
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Metabolic disorder DIS71G5H 5C50-5D2Z Phase 3 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Non-insulin dependent diabetes DISK1O5Z 5A11 Investigative [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of Takeda.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1612).